Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence

Core Insights - Pacira BioSciences Inc. (NASDAQ:PCRX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company presented data at the AAOS 2026 Annual Meeting, showcasing Exparel's benefits in pain management, including improved outcomes, reduced opioid use, and shorter hospital stays compared to standard treatments [1] - Iovera demonstrated longer-lasting pain relief and functional improvement, with benefits lasting up to 12 months, reinforcing the company's position in post-surgical pain management [3] Legislative Impact - A survey conducted by the Voices for Non-Opioid Choices coalition revealed the initial effects of the NOPAIN Act, which was implemented on January 1, 2025 [4][5] - 85% of facility representatives surveyed were aware of the NOPAIN Act, and over half of the facilities have made changes to increase the use of non-opioid options [5] - More than 80% of those surveyed reported a reduction in opioid prescribing for immediate post-surgery and discharge due to the legislation [5] Company Focus - Pacira BioSciences is dedicated to developing and marketing non-opioid pain management and regenerative health solutions, with a portfolio that includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device [6]